|
1) Kuruma H, Egawa S, Oh-Ishi M, et al. Proteome analysis of prostate cancer. Prostate Cancer Prostatic Dis. 2005; 8: 14-21
|
|
|
|
2) Bergerheim US, Soderhall M, Zabarovsky E, et al. Genotypic and phenotypic characterization of two newly established renal cell carcinoma cell lines. Cancer Genet Cytogenet. 1996; 86: 95-101
|
|
|
|
|
|
3) Sarto C, Marocchi A, Sanchez JC, et al. Renal cell carcinoma and normal kidney protein expression. Electrophoresis. 1997; 18: 599-604
|
|
|
|
|
|
4) Sarto C, Frutiger S, Cappellano F, et al. Modified expression of plasma glutathione peroxidase and manganese superoxide dismutase in human renal cell carcinoma. Electrophoresis. 1999; 20: 3458-66
|
|
|
|
|
|
5) Balabanov S, Zimmermann U, Protzel C, et al. Tumour-related enzyme alterations in the clear cell type of human renal cell carcinoma identified by two-dimensional gel electrophoresis. Eur J Biochem. 2001; 268: 5977-80
|
|
|
|
|
|
6) Dallmann K, Junker H, Balabanov S, et al. Human agmatinase is diminished in the clear cell type of renal cell carcinoma. Int J Cancer. 2004; 108: 342-7
|
|
|
|
|
|
7) Zimmermann U, Balabanov S, Giebel J, et al. Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination. Cancer Lett. 2004; 209: 111-8
|
|
|
|
|
|
8) Craven RA, Totty N, Harnden P, et al. Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis: evaluation of tissue preparation and sample limitations. Am J Pathol. 2002; 160: 815-22
|
|
|
|
|
|
9) Craven RA, Stanley AJ, Hanrahan S, et al. Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. Proteomics. 2006; 6: 2853-64
|
|
|
|
|
|
10) Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci U S A. 2004; 101: 13368-73
|
|
|
|
|
|
11) Zhou H, Pisitkun T, Aponte A, et al. Exosomal fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury. Kidney Int. 2006; 70: 1847-57
|
|
|
|
|
|
12) Celis JE, Ostergaard M, Basse B, et al. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Res. 1996; 56: 4782-90
|
|
|
|
|
|
13) Getzenberg RH, Konety BR, Oeler TA, et al. Bladder cancer-associated nuclear matrix proteins. Cancer Res. 1996; 56: 1690-4
|
|
|
|
|
|
14) Kageyama S, Isono T, Iwaki H, et al. Iden-tification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem. 2004; 50: 857-66
|
|
|
|
|
|
15) Iwaki H, Kageyama S, Isono T, et al. Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma -synuclein, and catechol-o-methyltransferase) identified by proteomic analysis. Cancer Sci. 2004; 95: 955-61
|
|
|
|
|
16) van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer survei-llance: a systematic review. Eur Urol. 2005; 47: 736-48
|
|
|
|
|
|
17) Vlahou A, Schellhammer PF, Mendrinos S, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol. 2001; 158: 1491-502
|
|
|
|
|
|
18) Grover PK, Resnick MI. Analysis of prostatic fluid: evidence for the presence of a prospective marker for prostatic cancer. Prostate. 1995; 26: 12-8
|
|
|
|
|
|
19) Alaiya A, Roblick U, Egevad L, et al. Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma. Anal Cell Pathol. 2000; 21: 1-9
|
|
|
|
|
|
20) Alaiya AA, Oppermann M, Langridge J, et al. Identification of proteins in human prostate tumor material by two-dimensional gel electrophoresis and mass spectrometry. Cell Mol Life Sci. 2001; 58: 307-11
|
|
|
|
|
|
21) Kuruma H, Egawa S, Oh-Ishi M. et al. High molecular mass proteome of androgen-independent prostate cancer. Proteomics. 2005; 5: 1097-112
|
|
|
|
|
|
22) Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 2002; 62: 3609-14
|
|
|
|
|